Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP-2
- Development stage
- Preclinical
- Lead developer
- MediaPharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Parenteral
01
Overview
SP-2 (also known as MP-1959) is a preclinical-stage monoclonal antibody developed by MediaPharma. It specifically targets Galectin-3 Binding Protein (LGALS3BP), a secreted glycoprotein that is highly expressed in various solid tumors and is associated with cancer progression, metastasis, and tumor angiogenesis. By binding to LGALS3BP, SP-2 aims to inhibit its pro-tumorigenic functions, particularly its role in promoting new blood vessel formation within the tumor microenvironment. The drug is being investigated for the treatment of breast cancer and colorectal cancer, leveraging its potential to disrupt tumor growth and vascularization.
- Other names
- anti-LGALS3BP monoclonal antibodyanti-LGALS-3BP monoclonal antibodyanti-LGALS 3BP monoclonal antibodyMP-1959MP1959MP 1959
02
Targets
LGALS3BP (Galectin-3-binding protein)
Beyond the preview
Go deeper on SP-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP-2.